文献速递脊柱外科骨质疏松与代谢性骨病创伤骨科

椎体骨折级联:潜在病因与危险因素

Vertebral fractures cascade: potential causes and risk factors.
PubMed 文献 · Osteoporos Int · 2018-12-05

本研究回顾性收集2016年1月至2017年4月10个中心的113例椎体骨折级联患者,其中仅约半数存在继发性骨质疏松病因;68.6%有骨密度骨质疏松,31.5%既往接受过抗骨质疏松治疗,部分病例发生在抗骨质疏松治疗停药后。

要点

  • 椎体骨折级联患者中仅约半数可识别继发性骨质疏松病因,68.6%有骨密度骨质疏松。
  • 31.5%患者既往接受过抗骨质疏松治疗,6例在停药后疗效耗竭期间发生级联。
  • 11.8%的病例发生在椎体成形术后。

核心结论

  • 这项回顾性研究显示,仅半数椎体骨折级联发生于存在继发性骨质疏松病因的患者。
  • 需要前瞻性研究进一步探索这一骨质疏松严重并发症的决定因素。

研究设计与样本

  • 回顾性收集2016年1月至2017年4月期间10个中心的椎体骨折级联观察资料。
  • 共纳入113例椎体骨折级联患者,其中女性占79.6%,中位年龄73岁,级联中椎体骨折中位数为5。
  • 椎体骨折级联定义为1年内发生至少3次椎体骨折。

主要发现

  • 40.5%患者有既往重大骨折史,30.9%有既往椎体骨折史,68.6%存在骨密度骨质疏松。
  • 18.9%患者正在使用口服糖皮质激素,37.1%既往使用过。
  • 医生将54%患者的椎体骨折级联归因于绝经后骨质疏松。
  • 52例患者诊断了与椎体骨折级联相关的继发性骨质疏松:糖皮质激素性骨质疏松25.7%、非恶性血液病6.2%、酒精中毒4.4%、芳香化酶抑制剂使用3.6%、原发性甲状旁腺功能亢进2.7%、皮质醇增多症2.7%、神经性厌食2.7%、妊娠及哺乳相关骨质疏松1.8%。
  • 11.8%的病例报告发生于椎体成形术后;31.5%患者既往接受过抗骨质疏松治疗;6例在抗骨质疏松治疗停药后早期发生级联,其中5例为地舒单抗后、1例为奥达卡替后,均发生于末次剂量疗效耗竭后1年内。

局限性

  • 本文为回顾性研究。
  • 需要前瞻性研究进一步探索这一骨质疏松严重并发症的决定因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We performed a study to identify potential causes and risk factors of vertebral fracture cascade. Vertebral fracture cascade is a severe clinical event in patients with bone fragility. Only half of patients have an identified cause of secondary osteoporosis. INTRODUCTION: Vertebral fracture (VF) is the most common osteoporotic fracture, and a strong risk factor of subsequent VFs leading to VF cascade (VFC). We prompted a study to identify potential causes and risk factors of VFC. METHODS: VFC observations were collected retrospectively between January 2016 and April 2017. VFC was defined as an occurrence of at least three VFs within 1 year. RESULTS: We included in 10 centers a total of 113 patients with VFC (79.6% of women, median age 73, median number of VFs in the cascade, 5). We observed 40.5% and 30.9% of patients with previous major fractures and a previous VF, respectively, and 68.6% with densitometric osteoporosis; 18.9% of patients were currently receiving oral glucocorticoids and 37.1% in the past. VFC was attributed by the physician to postmenopausal osteoporosis in 54% of patients. A secondary osteoporosis associated with the VFC was diagnosed in 52 patients: glucocorticoid-induced osteoporosis (25.7%), non-malignant hemopathies (6.2%), alcoholism (4.4%), use of aromatase inhibitors (3.6%), primary hyperparathyroidism (2.7%), hypercorticism (2.7%), anorexia nervosa (2.7%), and pregnancy and lactation-associated osteoporosis (1.8%). A total of 11.8% of cases were reported following a vertebroplasty procedure. A total of 31.5% patients previously received an anti-osteoporotic treatment. In six patients, VFC occurred early after discontinuation of an anti-osteoporotic treatment, in the year after the last dose effect was depleted: five after denosumab and one after odanacatib. CONCLUSION: The results of this retrospective study showed that only half of VFC occurred in patients with a secondary cause of osteoporosis. Prospective studies are needed to further explore the determinants of this severe complication of osteoporosis.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Che H, Breuil V, Cortet B, et al. Vertebral fractures cascade: potential causes and risk factors. Osteoporos Int. 2018. PMID: 30519756. doi:10.1007/s00198-018-4793-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。